InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 6,000 research and publications.
Research title with ★ indicates InBody recommended paper.

Effects of ipragliflozin on postprandial glucose metabolism and gut peptides in type 2 diabetes: a pilot study

H Ueno et al.
Used Parameters : BW, BMI, TBW, Muscle Mass, BFM, PBF

Publication Year : 2018

Country : Japan

Journal : Diabetes Therapy

Introduction Ipragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test, as well as to investigate the glucose-lowering mechanisms of ipragliflozin. Methods Nine Japanese patients with obesity and type 2 diabetes mellitus were treated with ipragliflozin (50 mg/day) for 12 weeks. The postprandial profiles of glucose, insulin …
Full text